Fuda Cancer Hospital, Guangzhou: Lung Neoplasms trials

The registry lists 15 Lung Neoplasms studies with Fuda Cancer Hospital, Guangzhou as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 10Phase 2 12Phase 3 1Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung CancerWithdrawnNCT03501056Phase 2
• Bioinformation Therapy for Lung CancerCompletedNCT03239171Phase 2/3
• Safety and Efficiency of γδ T Cell Against Lung CancerCompletedNCT03183232Phase 1/2
• High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung CancerCompletedNCT03007875Phase 1/2
• Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung CancerCompletedNCT02845856Phase 1/2
• Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung CancerCompletedNCT02843815Phase 1/2
• Cryotherapy Combine Icotinib for Advanced NSCLC TreatmentCompletedNCT02744664Phase 4
• HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA）for Lung CancerCompletedNCT02523404Phase 1/2
• Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung CarcinomaCompletedNCT02449122Phase 1/2
• Irreversible Electroporation(IRE) For Lung Neoplasms Accompanied by Respiratory Function InsufficiencyCompletedNCT02430753Not applicable
• Irreversible Electroporation(IRE) For Unresectable Hilus Pulmonis NeoplasmsCompletedNCT02430597Not applicable
• Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)CompletedNCT02425748Phase 1/2
• Safety and Efficacy of Mix Vaccine in Lung Carcinoma PatientCompletedNCT02333474Phase 1/2
• The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells VaccineCompletedNCT02115958Phase 1/2
• Vaccine Therapy in Treating Lung Cancer Patients With Cancer Stem CellsCompletedNCT02084823Phase 1/2